相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments
Amelie Boichard et al.
CANCERS (2020)
Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer
Qing Zhou et al.
GENOME MEDICINE (2020)
Technical Evaluation of Commercial Mutation Analysis Platforms and Reference Materials for Liquid Biopsy Profiling
Sabrina Weber et al.
CANCERS (2020)
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
Nicholas C Turner et al.
LANCET ONCOLOGY (2020)
Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer
Samantha O. Perakis et al.
ESMO OPEN (2020)
Molecular screening to select therapy for advanced cancer?
I. F. Tannock et al.
ANNALS OF ONCOLOGY (2019)
Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial
O. Tredan et al.
ANNALS OF ONCOLOGY (2019)
Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study
Dominic G. Rothwell et al.
NATURE MEDICINE (2019)
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
Jason K. Sicklick et al.
NATURE MEDICINE (2019)
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
Aparna R. Parikh et al.
NATURE MEDICINE (2019)
CNV Detection from Circulating Tumor DNA in Late Stage Non-Small Cell Lung Cancer Patients
Hao Peng et al.
GENES (2019)
Current and future perspectives of liquid biopsies in genomics-driven oncology
Ellen Heitzer et al.
NATURE REVIEWS GENETICS (2019)
An analysis of genetic heterogeneity in untreated cancers
Johannes G. Reiter et al.
NATURE REVIEWS CANCER (2019)
Tumour heterogeneity and resistance to cancer therapies
Ibiayi Dagogo-Jack et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients
Oliver A. Zill et al.
CLINICAL CANCER RESEARCH (2018)
Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
Justin I. Odegaard et al.
CLINICAL CANCER RESEARCH (2018)
Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology
John Marquart et al.
JAMA ONCOLOGY (2018)
Challenging Standard-of-Care Paradigms in the Precision Oncology Era
Vivek Subbiah et al.
TRENDS IN CANCER (2018)
Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit
Shumei Kato et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Integrating liquid biopsies into the management of cancer
Giulia Siravegna et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
Viktor A. Adalsteinsson et al.
NATURE COMMUNICATIONS (2017)
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
Christophe Massard et al.
CANCER DISCOVERY (2017)
Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH
Geraldine O'Sullivan Coyne et al.
CURRENT PROBLEMS IN CANCER (2017)
Liquid biopsies come of age: towards implementation of circulating tumour DNA
Jonathan C. M. Wan et al.
NATURE REVIEWS CANCER (2017)
Precision oncology: origins, optimism, and potential
Vinay Prasad et al.
LANCET ONCOLOGY (2016)
The precision-oncology illusion
Vinay Prasad
NATURE (2016)
Inferring expressed genes by whole-genome sequencing of plasma DNA
Peter Ulz et al.
NATURE GENETICS (2016)
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
Christophe Le Tourneau et al.
LANCET ONCOLOGY (2015)
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer
Muhammed Murtaza et al.
NATURE COMMUNICATIONS (2015)
Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders
David M. Hyman et al.
CANCER DISCOVERY (2015)
Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification
Raphael Brandao Moreira et al.
CASE REPORTS IN ONCOLOGY (2015)
The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma
Eliezer M. Van Allen et al.
CANCER DISCOVERY (2014)
Emerging landscape of oncogenic signatures across human cancers
Giovanni Ciriello et al.
NATURE GENETICS (2013)
Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing
Ellen Heitzer et al.
GENOME MEDICINE (2013)
State of the Art of the Therapeutic Perspective of Sorafenib Against Hematological Malignancies
G. Zauli et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma et al.
CELL (2010)
Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
Daniel D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Kai Wang et al.
NUCLEIC ACIDS RESEARCH (2010)
Fast and accurate short read alignment with Burrows-Wheeler transform
Heng Li et al.
BIOINFORMATICS (2009)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
Thomas O'Hare et al.
BLOOD (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
分享论文
